Solving America’s largest
drug problem

$552 billion is wasted annually when patients are prescribed drugs they don’t respond to.

We use a patient’s own molecular data to ensure optimal therapy is prescribed from day one, improving lives and saving money.

One test for
providers and payers.

A first-of-its kind blood based molecular signature test identifies a patient’s unique disease biology to determine which drug actually targets the disease, allowing providers and payers to make the right therapy decision to reach treatment goals.

Scipher molecular signature test
Hand with pill

Using data from molecular signature tests to develop more effective drugs for

Real world clinico-genomic data collected from our tests and analyzed by our AI platform reveals novel drug targets specific to biologically similar patient populations.

We partner across healthcare